ArticleParasites & vectors2025
Efficacy of a novel chewable tablet (Credelio Quattro
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy of Credelio Quattro™ chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs.Parasites & vectors · 2026Article
- Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.Parasites & vectors · 2026Article
- Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTOParasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoundworms such as Toxascaris leonina and Toxocara canis are routinely diagnosed in dogs globally, especially in dogs 6 months of age or younger. Toxocara canis is zoonotic, can cause significant disease in dogs, and is the causative agent of toxocariasis in humans. To protect both animal and human health, it is imperative that Toxocara canis infections are effectively treated and controlled to minimize the risk of transmission. The following studies were performed to demonstrate the effectiveness and safety of a novel, combination chewable tablet (Credelio Quattro
methodsSix well-controlled studies were performed. Two studies each evaluated Credelio Quattro against immature adult T. canis, adult T. canis, and adult T. leonina infections. Post-treatment efficacy was calculated from necropsy worm counts, and fecal egg count reduction was determined 10 days post-treatment in studies evaluating experimentally induced or naturally acquired adult infections.
resultsCredelio Quattro was safe and ≥ 97.9% effective against immature adult stages and ≥ 97.0% effective against adult stages of induced and natural T. canis infections in dogs. After treatment with Credelio Quattro, fecal egg counts were reduced by ≥ 98.8% in T. canis-infected dogs. In both experimentally induced and naturally acquired adult T. leonina infections in dogs, Credelio Quattro was safe and 100% effective in eliminating adult worms and provided 100% reduction in fecal egg counts post-treatment. The most common adverse events reported included digestive tract disorders such as diarrhea, mucus and/or blood in feces, vomiting, and expelled ascarid worms, which occurred in both control- and treated-groups.
conclusionsThese laboratory studies confirm the effectiveness and safety of a single dose of Credelio Quattro, administered at the minimum dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5 mg/kg praziquantel, and 5 mg/kg pyrantel, for the treatment and control of immature adult and adult T. canis and adult T. leonina in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.